THE drive of local entrepreneurs and curry restaurants has led to Bradford being named the UK’s most improved city, experts believe.
The West Yorkshire city was once notorious for race riots in 2001, a long-delayed shopping centre and high levels of unemployment.
However, research by PricewaterhouseCoopers and think tank Demos put it top of the charts ahead of Liverpool, Norwich, Newcastle and Cardiff. And researchers hailed Bradford’s better work-life balance, more pleasant environment and residents’ better health.
There has also been a drop in unemployment, from 10 per cent in 2015 to 4.1 per cent last year, and an increase in the number of skilled workers.
The city – where one in five people are of Pakistani origin – is now famous for having Britain’s oldest concert hall in Britain St George’s Hall and Bradford Broadway shopping centre.
Naz Shah, Labour’s parliamentary candidate for Bradford West, said the accolade is a testament to the fantastic work taking place across the area.
She told Eastern Eye: “Bradford over recent years has celebrated the rich diversity this city inherits, rather than to hide away from it. Alongside this, the city’s growing young population has also been a focal point in transforming the image of Bradford.
“Bradford is inclusive, diverse and young and we are proud of it.”
The study said Oxford was the most attractive city in the country, followed by Reading, Southampton, Bristol and Milton Keynes.
The index ranks urban areas with populations of more than 250,000 on ten measures including high-quality jobs, distribution of income, affordable housing, transport networks and the local environment.
The highest ranked big city this year was Bradford’s neighbour Leeds, which came in 11th.
Usman Younas, who runs Watan Supermarket in Bradford, told Eastern Eye: “A lot of people have bad things to say because of the stereotypes, negative press, social media – but what actually happens here is a different thing.
“The amount of businesses is quite high compared to other places, there is a takeaway or cash and carry on each corner, it’s densely populated with businesses – people come far and wide for food, shisha, getting their car done, clothes.
“They employ people from different backgrounds, I have Hungarians, Indians, Pakistanis working for me. The councillors and local MPs are always out doing something, they are very welcoming. People are always looking for work, a lot are in poverty; they don’t want to sit on their backside.”
Famous British Asian Bradfordians include singer Zayn Malik; Naveed Ikram, the first Muslim woman to become a Lord Mayor in the UK; England cricketer Adil Rashid; and TV presenter Anita Rani.
The city also has a thriving arts scene with an annual literature festival, a National Science and Media museum, and Salts Mill, a refurbished former mill that also houses a collection from painter David Hockney.
Professor Mahendra Patel grew up in Bradford and said its location in the valleys and size made it a unique place.
The honorary visiting professor in pharmacy for the University of Bradford said: “It has become more diverse, it has brought unique cultures that other cities can look towards.
“Also the different religious practices, the large eclectic mix in schools and universities. The recession, the turbulence and unrest, it has gone through that and bounced back.”
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.